These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26244069)

  • 1. Hepatitis C: Treatment of difficult to treat patients.
    Hilgenfeldt EG; Schlachterman A; Firpi RJ
    World J Hepatol; 2015 Jul; 7(15):1953-63. PubMed ID: 26244069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.
    Cachay ER; Wyles D; Hill L; Ballard C; Torriani F; Colwell B; Kuo A; Schooley R; Mathews CW
    Open Forum Infect Dis; 2015 Dec; 2(4):ofv168. PubMed ID: 26697509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
    Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
    BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hepatitis C virus genotype 3-infection.
    Pol S; Vallet-Pichard A; Corouge M
    Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
    Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV;
    Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
    Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
    J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era.
    Nordien R; Sonderup MW; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):106-111. PubMed ID: 32657679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
    Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
    Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
    Zheng YX; Ma SJ; Xiong YH; Fan XG
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1477-1487. PubMed ID: 32246857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review.
    Mantry PS; Pathak L
    Expert Rev Anti Infect Ther; 2016; 14(2):157-65. PubMed ID: 26567871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.
    Yang YM; Choi EJ
    Ther Clin Risk Manag; 2017; 13():477-497. PubMed ID: 28442915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Welch NM; Jensen DM
    Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
    Naik GS; Tyagi MG
    J Clin Exp Hepatol; 2012 Mar; 2(1):42-54. PubMed ID: 25755405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
    Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.